Numinus Wellness Inc said it has received conditional approval for listing on the Toronto Stock Exchange (TSX), moving up from its listing on the TSX Venture Exchange.
"This is an important milestone for Numinus, as we take key steps to heighten our corporate profile and reach a broader range of investors," said Payton Nyquvest, CEO of Numinus in a statement.
He added that the announcement is reflective of many “exciting developments” occurring at Numinus.
Upon listing on the TSX, the company's shares will continue to trade under the symbol NUMI, and its outstanding listed warrants will continue to trade under the symbols NUMI.WT, NUMI.WT.B and NUMI.WT.C, the company said.
READ: Numinus Wellness advances Phase 1 trial on its proprietary psilocybin product PSYBINA
“We're actively growing our clinic network across North America, expanding our lab capabilities, and strategically investing in clinical research to drive long-term value creation for our investors," Nyquvest said.
The Vancouver, British Columbia-based company said that it is working to satisfy the listing conditions provided by the TSX.
Former chief strategy officer departs
In a separate announcement, Numinus Wellness also said that following the conclusion of several weeks of discussions that Stacey Wallin, former chief strategy officer, is no longer with the company.
"During Stacey's three years with Numinus, she was integral to the development of foundational operations necessary to support the growth of Numinus. We thank Stacey for her contributions and wish her the best in her future endeavors," said Numinus CEO Nyquvest.
"Our growing and talented team continues to execute on our mission to be the most trusted brand in the space – we are excited for what's yet to come as we seek to help more people through innovative mental health care and psychedelic-assisted therapies, he added.
Wallin's responsibilities have been transitioned across Numinus' leadership team. As part of the separation agreement, Numinus has agreed to issue her 2,000,000 common shares from Treasury.
Numinus is looking to help people heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies.
The Numinus model – including psychedelic production, research, and clinic care – is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain, and substance use.
Contact Ritika at ritika@proactiveinvestors.com